MEREO BIOPHARMA GROUP PL-ADR (MREO)
US5894921072 - ADR
Overall MREO gets a fundamental rating of 2 out of 10. We evaluated MREO against 587 industry peers in the Biotechnology industry. While MREO seems to be doing ok healthwise, there are quite some concerns on its profitability. MREO has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year MREO has reported negative net income.
In the past year MREO has reported a negative cash flow from operations.
In the past 5 years MREO reported 4 times negative net income.
MREO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a decent Return On Assets value of -32.33%, MREO is doing good in the industry, outperforming 69.40% of the companies in the same industry.
With a decent Return On Equity value of -45.14%, MREO is doing good in the industry, outperforming 71.28% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.33% | ||
| ROE | -45.14% | ||
| ROIC | N/A |
ROA(3y)-96.3%
ROA(5y)-75.36%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MREO has a better Gross Margin (73.75%) than 85.13% of its industry peers.
MREO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 73.75% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
MREO does not have a ROIC to compare to the WACC, probably because it is not profitable.
MREO has more shares outstanding than it did 1 year ago.
MREO has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, MREO has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 4.55 indicates that MREO is not in any danger for bankruptcy at the moment.
MREO has a Altman-Z score of 4.55. This is in the better half of the industry: MREO outperforms 77.78% of its industry peers.
A Debt/Equity ratio of 0.08 indicates that MREO is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.08, MREO is doing worse than 62.91% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.55 |
ROIC/WACCN/A
WACC8.48%
2.3 Liquidity
MREO has a Current Ratio of 3.11. This indicates that MREO is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of MREO (3.11) is worse than 65.98% of its industry peers.
A Quick Ratio of 3.11 indicates that MREO has no problem at all paying its short term obligations.
MREO's Quick ratio of 3.11 is on the low side compared to the rest of the industry. MREO is outperformed by 64.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.11 | ||
| Quick Ratio | 3.11 |
3. Growth
3.1 Past
MREO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -31.83%.
The Revenue for MREO has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-31.83%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q46.39%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
Based on estimates for the next years, MREO will show a small growth in Earnings Per Share. The EPS will grow by 2.65% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y42.05%
EPS Next 2Y36.37%
EPS Next 3Y13.3%
EPS Next 5Y2.65%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
MREO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MREO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
MREO's earnings are expected to grow with 13.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.37%
EPS Next 3Y13.3%
5. Dividend
5.1 Amount
No dividends for MREO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MEREO BIOPHARMA GROUP PL-ADR
NASDAQ:MREO (5/16/2024, 7:05:26 PM)
After market: 3.17 -0.1 (-3.06%)3.27
+0.1 (+3.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap458.69M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.33% | ||
| ROE | -45.14% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 73.75% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.11 | ||
| Quick Ratio | 3.11 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-31.83%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y42.05%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y